Effects of pindolol on serum lipoproteins and postheparin lipolytic activities in hypertensive patients.
Thirty-four hyperlipoproteinemic, hypertensive patients received 5 mg of pindolol twice daily for 12 weeks. During pindolol administration, there were significant decreases in serum triglyceride levels and increases in high-density lipoprotein cholesterol (HDL-C) levels, while total cholesterol levels did not change. Serum levels of very-low-density lipoprotein (VLDL) triglyceride and VLDL cholesterol decreased over time as HDL-C increased. There was a significant increase in low-density lipoprotein cholesterol at week 12. Apolipoprotein (apo) A-I, A-II, and B levels did not change during pindolol administration, but apo C-II, C-III, and E levels decreased significantly. Lipoprotein lipase activity in heparin-treated plasma was significantly higher after pindolol administration. The results suggest that the reduction in triglyceride levels and increase in HDL-C after pindolol are partly a response to an increase in the hydrolysis of VLDL resulting from an increase in lipoprotein lipase activity.
Sasaki
N
N
Department of Internal Medicine, Kawatetsu Chiba Hospital, Japan.
Saito
Y
Y
Shinomiya
M
M
Kanzaki
T
T
Ishikawa
Y
Y
Mori
S
S
Kobayashi
J
J
Murano
S
S
Nishide
T
T
Morisaki
N
N
D001053:Apolipoproteins / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D006493:Heparin / Q000494:pharmacology*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood; D006973:Hypertension / Q000097:blood* / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008066:Lipolysis / Q000187:drug effects*; D008074:Lipoproteins / Q000097:blood*; D010869:Pindolol / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood
D001053:Apolipoproteins; D008076:Cholesterol, HDL; D015243:Cholesterol, VLDL; D008055:Lipids; D008074:Lipoproteins; D014280:Triglycerides; D006493:Heparin; D010869:Pindolol